Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
724.54
+9.95 (1.39%)
At close: Sep 26, 2025, 4:00 PM EDT
722.08
-2.46 (-0.34%)
After-hours: Sep 26, 2025, 7:59 PM EDT
Eli Lilly Revenue
Eli Lilly had revenue of $15.56B in the quarter ending June 30, 2025, with 37.64% growth. This brings the company's revenue in the last twelve months to $53.26B, up 36.83% year-over-year. In the year 2024, Eli Lilly had annual revenue of $45.04B with 32.00% growth.
Revenue (ttm)
$53.26B
Revenue Growth
+36.83%
P/S Ratio
12.24
Revenue / Employee
$1,133,151
Employees
47,000
Market Cap
650.45B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Novo Nordisk | 49.11B |
Thermo Fisher Scientific | 43.21B |
LLY News
- 1 day ago - A New Prescription For Pain: Understanding Trump's 100% Pharma Tariff - Seeking Alpha
- 1 day ago - Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem - PRNewsWire
- 1 day ago - Eli Lilly, Pfizer Stocks Rise After Trump's 100% Pharma Tariff Threat. Here's Why. - Barrons
- 2 days ago - Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease - PRNewsWire
- 2 days ago - US FDA approves Eli Lilly's therapy for metastatic breast cancer - Reuters
- 2 days ago - U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer - PRNewsWire
- 2 days ago - Eli Lilly and Company (LLY) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 2 days ago - Eli Lilly: Buying The Dip With Confidence - Seeking Alpha